Clinical Trial

Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]

Suspended Phase 2
View on ClinicalTrials.gov →
Why the trial stopped
PI requested
Summary
To learn about the effects of the drugs regorafenib and lorigerlimab on circulating tumor DNA (ctDNA) in patients with CRC and who have radiographic occult minimal residual disease (MRD) after completing standard-of-care therapy
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-16; most recent amendment 2026-06-03.
Status change: Not Yet Recruiting → Suspended 2026-02-11
Trial Details
NCT Number NCT07071961
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Bayer, MacroGenics
Conditions Colorectal Cancer, Regorafenib, High Risk Patients
Enrollment 16 participants
Start Date 2026-02-11
Primary Completion 2027-05-01 (estimated)
Study Completion 2029-05-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-05